The Daybue trial data results are valuable and it provided Acadia with FDA approval. I don't think it is wise to promote NNZ2591 for Rhett in the USA or anywhere else as it doesn't have the Rhett trial data to support it.
I am wondering if the NNZ2591 Angelman Trial results are positive, whether NEU will announce the other syndrome NEU is considering for this drug before it meets with the FDA in September 2024 - would make sense to raise the expanding potential of NNZ2591 with FDA at that point into time.
Ann: Trading Halt, page-33
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.61 |
Change
0.280(2.10%) |
Mkt cap ! $1.739B | |||
| Open | High | Low | Value | Volume |
| $13.49 | $13.64 | $13.30 | $4.821M | 356.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 3602 | $13.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.66 | 1655 | 2 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |